Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria

BMC Gastroenterology

Table 4 Health economic results of colorectal cancer screening programs

Screening Strategy	LYG	Disc. LYG	Costs [EUR]	Disc. costs [EUR]	Disc. incr. LYG	Disc. incr. Costs [EUR]	ICER [EUR/LYG]
No Screening	–	–	2890	1138	–	–	dominated
10-yearly Colonoscopy	0.39	0.12	1440	754
Annual gFOBT	0.48	0.15	2341	1398	–	–	dominated
Annual FIT	0.49	0.16	2257	1352	0.04	598	14,960

LYG Life-years gained compared to No Screening per individual, disc Discounted, ICER Incremental cost-effectiveness ratio, gFOBT Guaiac-fecal occult blood test screening strategy, FIT Fecal immunochemical test screening strategy, EUR Euro. FIT and gFOBT: 40–75 years old average - risk men and women. Colonoscopy: 50–70 years old average - risk men and women, all screening strategies include index testing, further diagnostics (including colonoscopy), surveillance (colonoscopy), treatment and follow up interventions. Full adherence to screening strategies including follow-up and surveillance tests was assumed.

ISSN: 1471-230X